Dodge & Cox Reduces Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Dodge & Cox trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 27.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,321,230 shares of the biopharmaceutical company’s stock after selling 875,866 shares during the period. Dodge & Cox’s holdings in Alnylam Pharmaceuticals were worth $1,058,481,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Root Financial Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $25,000. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $27,000. Ameriflex Group Inc. purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth about $32,000. Aster Capital Management DIFC Ltd purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth about $36,000. Finally, ORG Partners LLC raised its stake in Alnylam Pharmaceuticals by 70.2% in the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 33 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ALNY has been the topic of several recent research reports. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Barclays started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price target on the stock. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research note on Friday, January 30th. Needham & Company LLC cut their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Trading Down 1.2%

Shares of ALNY opened at $313.41 on Friday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The company has a market capitalization of $41.56 billion, a P/E ratio of 183.28 and a beta of 0.36. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The firm’s 50 day simple moving average is $344.35 and its 200 day simple moving average is $410.04.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.Alnylam Pharmaceuticals’s quarterly revenue was up 84.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.65) EPS. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total transaction of $528,193.96. Following the completion of the sale, the executive vice president owned 21,860 shares of the company’s stock, valued at $6,989,297.80. The trade was a 7.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $722,795.90. Following the completion of the transaction, the executive vice president owned 64,273 shares of the company’s stock, valued at $21,059,048.45. The trade was a 3.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 53,923 shares of company stock worth $18,072,087 in the last three months. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.